The RAPS learning platform provider will be upgrading its security posture. This will take the system off-line from 20 July through the end of the day 23 July. This will affect any Online Course, eBook, and Virtual Program Attendance. Thank you for your patience.
The US Approval Pathway for Biosimilar Products
Posted 01 October 2010 | By
As part of the recently passed healthcare reform legislation, the US Congress finally amended the Public Health Service Act to allow approval of biosimilars in the US. President Obama signed the Patient Protection and Affordable Care Act into law on 22 March 2010. The law incorporates a specific subsection dealing with biosimilars entitled the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Consistent with the terminology used elsewhere in the world, the legislation uses "biosimilars" when referring to these biopharmaceutical products instead of "follow-on biologics" or some other term, helping to avoid further confusion in this arena.